Robert Dullea, Ph.D

Robert is an experienced scientist and project leader with years of experience in advancing cardiometabolic drug targets from idea through clinical development. He has co-authored numerous peer-reviewed research publications and is a patents co-inventor.  Robert received his B.S. in Biology from Northeastern University, and his Ph.D. in Cellular and Molecular Radiation Biology and Cytogenetics from Colorado State University. During his post-doctoral training in the Oncology department at Pfizer, Inc., Robert developed an interest in translating early bench science to drug discovery.  In 2001, Robert took a full-time role at Pfizer supervising a functional genomics laboratory focused on applying multiple technologies to understand compound mechanism(s) of action. In 2008, he transitioned to the Internal Medicine Group at Pfizer where he led a biologics group utilizing mAb, Fc fusion and antisense-based therapeutics for the treatment of diabetes and cardiovascular disease. Currently, Robert is responsible for leading multidiscipline drug discovery teams from project initiation to Phase 2 proof of concept.  In this role he has led efforts to develop a novel small molecule approach targeting PCSK9 and leads many ongoing clinical programs for the treatment of MASH, HFpEF and chronic weight management.